Gene

BARD1

BRCA1 associated RING domain 1

Explore in graph →CI-GENE-00021621HGNC:952 ENSG00000138376 NCBI 580 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BARD1 G320*1
Carboplatin + GemcitabineCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted

Cohorts

Alteration frequency by cohort (73)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved73 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (3)

25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
· N Engl J Med · 2020 · PMID 32343890 · validated civic_curation pubmed
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
· Sci Rep · 2016 · PMID 27197561 · validated civic_curation pubmed
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.
· NPJ Precis Oncol · 2023 · PMID 36964191 · validated civic_curation pubmed

BARD1 ISOFORM EXPRESSION1
Apitolisib + OlaparibCombination	Pleural Malignant MesotheliomaALIAS	Predictive	D	Supports Sensitivity Response	3	rejected	EID5998 MPM cells transfected with BAP1Δ, an alternative splice isoform of BAP1 that misses part of the catalytic domain, showed reduced deubiquitinating activity compared with full-length BAP1. MPM cell line… (full text at CIViC) PMID 28389374 · Parrotta et al., 2017 · Open in CIViC	civic

BARD1 ISOFORM EXPRESSION1

Apitolisib + OlaparibCombination

Pleural Malignant MesotheliomaALIAS

Predictive

Supports Sensitivity Response

rejected

EID5998

MPM cells transfected with BAP1Δ, an alternative splice isoform of BAP1 that misses part of the catalytic domain, showed reduced deubiquitinating activity compared with full-length BAP1. MPM cell line… (full text at CIViC)

PMID 28389374 · Parrotta et al., 2017 · Open in CIViC

civic

BARD1 Loss-of-function1
Olaparib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID5953 Loss of BARD1 function through the expression of a BARD1 splice variant, BARD1β, results in a more malignant phenotype with decreased RAD51 foci formation, reduced BRCA1 E3 ubiquitin ligase activity, … (full text at CIViC) PMID 27197561 · Ozden et al., 2016 · Open in CIViC	civic

BARD1 Loss-of-function1

Olaparib

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID5953

Loss of BARD1 function through the expression of a BARD1 splice variant, BARD1β, results in a more malignant phenotype with decreased RAD51 foci formation, reduced BRCA1 E3 ubiquitin ligase activity, … (full text at CIViC)

PMID 27197561 · Ozden et al., 2016 · Open in CIViC

civic

BARD1 Mutation1
Olaparib	Castration-Resistant Prostate Carcinoma	Predictive	A	Supports Sensitivity Response	2	accepted	EID11209 This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC	civic

BARD1 Mutation1

Olaparib

Castration-Resistant Prostate Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID11209

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

civic